Bayer will relaunch Alka-Seltzer Plus as Alka-Seltzer Cold in 2026, the company announced, replacing the existing brand name with a simpler identity aimed at the cough and cold aisle. The relaunch introduces streamlined packaging designed to help consumers quickly identify the right cough and cold option, along with value-focused options including affordable price points and entry sizes, and a money-back guarantee on Alka-Seltzer Cold products. Trevor Thrun, U.S. President of Bayer Consumer Health, said the symptom-led pack design helps shoppers choose the right product when they are sick. The rollout is planned for 2026 across USA National Mass, Drug and Food Retailers. Bayer reported fiscal 2024 sales of 46.6 billion euros, around 93,000 employees and R&D expenses of 6.2 billion euros.
Bayer AG NABayer relaunches Alka-Seltzer Plus as Alka-Seltzer Cold with value-focused affordable price points, entry sizes, and a money-back guarantee.
